Indeed, treatment modalities for patients with metastatic non-small cell lung cancer have changed since the US FDA approved c-MET inhibitors such as capmatinib (Tabrecta®) and tepotinib (Tepmetko®). The gene discussed is MET; the disease is non-small cell lung carcinoma.